Uric acid lowering in relation to HbA1c reductions with the SGLT2 inhibitor tofogliflozin-Reference-Cited by-同舟云学术

Uric acid lowering in relation to HbA1c reductions with the SGLT2 inhibitor tofogliflozin

Published:2018-01-08 Issue:4 Volume:20 Page:1061-1065
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:Diabetes Obes Metab

Author:

Ouchi Motoshi¹,Oba Kenzo²,Kaku Kohei³^ORCID,Suganami Hideki⁴^ORCID,Yoshida Akihiro⁵,Fukunaka Yasunori⁶,Jutabha Promsuk¹,Morita Asuka¹,Otani Naoyuki⁷,Hayashi Keitaro¹,Fujita Tomoe¹,Suzuki Tatsuya⁸,Yasutake Masahiro⁸⁹,Anzai Naohiko¹⁰

Affiliation:

1. Department of Pharmacology and Toxicology; Dokkyo Medical University School of Medicine; Tochigi Japan

2. Department of Internal Medicine; Oarai Coast Core Clinic; Ibaraki Japan

3. Department of General Internal Medicine; Kawasaki Medical School; Okayama Japan

4. Clinical Data Science Department; Kowa Company, Ltd.; Tokyo Japan

5. Medical Information and Product Advancement Department; Kowa Pharmaceutical Company, Ltd.; Tokyo Japan

6. Product Strategy Department; Kowa Company, Ltd.; Tokyo Japan

7. Department of Clinical Pharmacology and therapeutics; Oita University Faculty of Medicine; Oita Japan

8. Division of Geriatric Medicine, Department of General Medicine and Health Science; Nippon Medical School; Tokyo Japan

9. Department of General Medicine and Health Science; Nippon Medical School; Tokyo Japan

10. Department of Pharmacology; Chiba University Graduate School of Medicine; Chiba Japan

Funder

Chugai Pharmaceutical Co., Ltd.

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/dom.13170/fullpdf

Reference19 articles.

1. Haemoglobin A1c, fasting glucose, serum C-peptide and insulin resistance in relation to serum uric acid levels--the Third National Health and Nutrition Examination Survey;Choi;Rheumatology (Oxford),2008

2. Efficacy and safety of monotherapy with the novel sodium/glucose cotransporter-2 inhibitor tofogliflozin in Japanese patients with type 2 diabetes mellitus: a combined phase 2 and 3 randomized, placebo-controlled, double-blind, parallel-group comparative study;Kaku;Cardiovasc Diabetol,2014

3. A novel and selective sodium-glucose cotransporter-2 inhibitor, tofogliflozin, improves glycaemic control and lowers body weight in patients with type 2 diabetes mellitus;Ikeda;Diabetes Obes Metab,2015

4. Efficacy and safety of tofogliflozin in Japanese patients with type 2 diabetes mellitus with inadequate glycaemic control on insulin therapy (J-STEP/INS): Results of a 16-week randomized, double-blind, placebo-controlled multicentre trial;Terauchi;Diabetes Obes Metab,2017

5. Long-term safety and efficacy of tofogliflozin, a selective inhibitor of sodium-glucose cotransporter 2, as monotherapy or in combination with other oral antidiabetic agents in Japanese patients with type 2 diabetes mellitus: multicenter, open-label, randomized controlled trials;Tanizawa;Expert Opin Pharmacother,2014

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Hyperuricemia and Gout Reduction by SGLT2 Inhibitors in Diabetes and Heart Failure;Journal of the American College of Cardiology;2024-01

2. Effect of baseline urinary glucose levels on the relationship between sodium-glucose cotransporter 2 inhibitors and serum uric acid in Japanese patients with type 2 diabetes mellitus;PHARMAZIE;2023

3. Changes in the estimated glomerular filtration rate and predictors of the renal prognosis in Japanese patients with type 2 diabetes: A retrospective study during the 12 months after the initiation of tofogliflozin;PLOS ONE;2023-09-21

4. Sodium–Glucose Cotransporter 2 Inhibitors to Decrease the Uric Acid Concentration—A Novel Mechanism of Action;Journal of Cardiovascular Development and Disease;2023-06-22

5. Sodium-glucose cotransporter-2 inhibitors use and the risk of gout: a systematic review and meta-analysis;Frontiers in Endocrinology;2023-05-23